Company Directory / research
PrivateFor profitresearchAmsterdam, Netherlands
Scenic Biotech
Scenic Biotech is a developer of a genomics and immunotherapy technologies created to unlock genetic suppressors.
- Founded
- 2017 9 years ago
- Staff
- 11-50 band, as listed
- Followers
- - on LinkedIn
- Funding
- $38M as listed, currency not stated
Set against six million companies
Size
11-50 people: larger than 33% of companies with a size listed
Age
9 years old.
Reach
Website ranked #14,093,485 in the world for traffic, about 60 visits a month.
What it does
BiometricsBiotechnologyCollaborative ConsumptionLife Science
Funding, as listed
$38M currency not stated
- Rounds3
- LatestSeries a, Mar 2022
- Investors8, 6 leading
What the source datasets report. We have not watched these rounds ourselves.
Every detail we hold
Everything the source datasets list about Scenic Biotech, field by field. Contact details are held but never shown.
The company
- Name
- Scenic Biotech
- Type
- For profit
- Status
- Private
- Founded
- 2017
- Founders
- Sebastian Nijman, Thijn Brummelkamp
- Industry
- research
- Categories
- Biometrics, Biotechnology, Collaborative Consumption, Life Science
Where
- City
- Amsterdam
- Country
- Netherlands
- Markets
- European Union (EU), Europe, Middle East, and Africa (EMEA)
Size and reach
- Staff band
- 11-50
- Web traffic rank
- #14,093,485
- Monthly web visits
- 60
Funding, as listed
- Total
- 37,600,000 (currency not stated)
- Rounds
- 3
- Latest round
- Series a
- Latest round date
- Mar 2022
- Investors
- 8
- Lead investors
- 6
- Listing status
- private
About this record
- Sources
- Crunchbase
- Last imported
- Sept 2026
Growth, as the source summarises it
Scenic Biotech may be growing as it has announced positive preclinical data for its QPCTL inhibitor SC-2882, which is a potential new therapeutic approach for Diffuse Large B-Cell Lymphoma. Additionally, the company has entered into a research collaboration with Bristol Myers Squibb, which could indicate an expansion of its research capabilities and potential revenue streams. The testing of its QPCTL inhibitor SC-2882 for a specific lymphoma further suggests ongoing product development and investment in its therapeutic pipeline.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
research in Netherlands.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 174,966 companies in Netherlands and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.